Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$4.44
-$0.22(-4.44%)
At close: 4:00 PM EDT
$4.44
-$0.22(-4.44%)
Day’s Range― - ―
52-Week Range$2.42 - $8.51
Previous Close$4.73
Volume74.35K
Average Volume (3M)270.74K
Market Cap
$110.28M
Enterprise Value$200.97M
Total Cash (Recent Filing)$17.76M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume354,959
30 Day Avg. Volume270,741
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap1.82
Enterprise Value/Revenue120.34
Enterprise Value/Gross Profit1.08K
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
$9.67Price Target Upside117.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$882.80K
Bulls Say, Bears Say
Bulls Say
FDA Authorization ProgressProgress toward FDA authorization could unlock broader commercialization of GraftAssureDx and validate the company’s kitted testing strategy. The larger study dataset and planned SIR meeting support regulatory execution, while authorization would expand access beyond current limited revenue channels.
Expanded Medicare Testing OpportunityThe 75% increase in covered surveillance testing strengthens the economic case for transplant monitoring and expands potential test utilization. Greater reimbursement-supported frequency can improve customer adoption, enlarge the addressable market, and support recurring demand if the company secures authorization.
Clinical Positioning And Customer EngagementReportedly favorable head-to-head performance and engagement across leading transplant centers provide evidence of clinical relevance and commercial interest. This combination may help the company establish credibility with reference labs and support adoption of its transplant monitoring platform over time.
Bears Say
Small, Declining Revenue Base And Weak MarginsThe current revenue base remains too small to support the cost structure, while declining sales and an approximately 11% gross margin limit operating leverage. Deep losses indicate that meaningful commercialization and sustained revenue growth are still required before the model can become self-funding.
Heavy Cash Burn And Negative EquitySubstantial operating and free-cash-flow deficits indicate continued reliance on external capital while revenue remains limited. Negative equity further reduces financial flexibility, making funding needs more consequential and increasing the risk that investment in growth will be constrained if commercialization takes longer.
FDA Timing And Commercialization DelaysA delayed FDA decision would postpone the broader commercial launch of GraftAssureDx and defer the revenue ramp that underpins the company’s growth plan. Additional data and SIR requirements create execution uncertainty, extending the period of losses and potentially increasing capital needs.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.42 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $110.28M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 10, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.056.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,724,285 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -7.128%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (117.72% Upside)
$9.67 (117.72% Upside)
Blogger Sentiment
Bearish
IMDX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.31%
12-Months-Change
Fundamentals
Return on Equity
271.76%
Trailing 12-Months
Asset Growth
-41.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
IMDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$9.67
▲(117.72% Upside)
Technical Analysis
Ownership Overview
78.79% Insiders
2.25% Mutual Funds
3.21% Other Institutional Investors
13.40% Public Companies and
Individual Investors